

ZOLOFT[®]

(Sertraline hydrochloride)

1. NAME OF THE MEDICINAL PRODUCT

ZOLOFT[®]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Sertraline is available as film-coated tablets for oral administration containing sertraline hydrochloride equivalent to 50 mg and 100 mg sertraline.²

3. PHARMACEUTICAL FORM

Film-coated tablets²

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

Sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania.^{4,5,6,7,8,9} Following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.^{10,11}

Sertraline is indicated for the treatment of obsessive-compulsive disorder (OCD).^{12,13,14,15} Following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of OCD.²¹²

Sertraline is indicated for the treatment of pediatric patients 6 years of age and older with OCD.¹⁶

Sertraline is indicated for the treatment of panic disorder, with or without agoraphobia.¹⁷ Following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of panic disorder.²¹³

Sertraline is indicated for the treatment of post-traumatic stress disorder (PTSD).¹⁶⁵ Following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of PTSD.²¹⁴

Sertraline is indicated for the treatment of social phobia (social anxiety disorder).²¹⁵ Following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of social phobia.²¹⁶

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

Sertraline should be administered once daily, either in the morning or evening.¹⁸

Sertraline tablets can be administered with or without food.¹⁹

Initial Treatment

Depression and OCD

Sertraline treatment should be administered at a dose of 50 mg/day.^{4,5,20,21}

Panic Disorder, PTSD, and Social Phobia²¹⁵

Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early-treatment-emergent side effects characteristic of panic disorder.^{17,165}

Titration

Depression, OCD, Panic Disorder, PTSD, and Social Phobia²⁵⁰

Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be made at intervals of at least one week, up to a maximum of 200 mg/day.^{4,12,16,17,22,23,165,250} Changes in dose should not be made more frequently than once per week given the 24-hour elimination half-life of sertraline.¹⁶⁵

The onset of therapeutic effect may be seen within 7 days. However, longer periods are usually necessary to demonstrate therapeutic response, especially in OCD.^{12,17,24,164}

Maintenance

Dosage during long-term therapy should be kept at the lowest effective level, with subsequent adjustment depending on therapeutic response.^{12,17,23,165}

Use in Children

The safety and efficacy of sertraline have been established in pediatric OCD patients aged 6 to 17 years. The administration of sertraline to pediatric OCD patients (aged 13 to 17 years) should commence at 50 mg/day. Therapy for pediatric OCD patients (aged 6 to 12 years) should commence at 25 mg/day, increasing to 50 mg/day after one week. Subsequent doses may be increased in case of lack of response in 50 mg/day increments, up to 200 mg/day, as needed. In a clinical trial in patients aged 6 to 17 years with depression or OCD, sertraline appeared to have a similar pharmacokinetic profile to that found in adults. However, the generally lower body weights of children compared to those of adults should be taken into consideration when increasing the dose from 50 mg.^{16,25}

Titration in Children and Adolescents

Sertraline has an elimination half-life of approximately one day; dose changes should not occur at intervals of less than one week.¹⁶

Use in the Elderly

The same dose range as in younger patients may be used in the elderly. Over 700 elderly patients (>65 years) have participated in clinical studies that demonstrated the efficacy of sertraline in this patient population.^{26,27,28,29} The pattern and incidence of adverse reactions in the elderly were similar to that in younger patients.²²

Use in Hepatic Insufficiency

The use of sertraline in patients with hepatic disease should be approached with caution. A lower or less frequent dose should be used in patients with hepatic impairment³⁰ (see section **4.4. Special Warnings and Precautions for Use**).

Use in Renal Insufficiency

Sertraline is extensively metabolized. Excretion of unchanged drug in urine is a minor route of elimination. As expected from the low renal excretion of sertraline, sertraline dosing does not have to be adjusted based on the degree of renal impairment^{30,31,32} (see section **4.4. Special Warnings and Precautions for Use**).

4.3. CONTRAINDICATIONS

Sertraline is contraindicated in patients with a known hypersensitivity to sertraline.³³

Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated (see section **4.4. Special Warnings and Precautions for Use**).³⁴

Concomitant use in patients taking pimozide is contraindicated (see section **4.5. Interaction with Other Medicinal Products and Other Forms of Interaction**).²¹⁷

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USESerotonin Syndrome

The development of potentially life-threatening syndromes like serotonin syndrome (SS) or neuroleptic malignant syndrome (NMS) has been reported with selective serotonin reuptake inhibitors (SSRIs), including treatment with sertraline. The risk of SS or NMS with SSRIs is increased with concomitant use of serotonergic drugs [including amphetamines,²⁴⁶ triptans, and opioids²⁵³ (e.g., fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine)],²³³ with drugs that impair metabolism of serotonin (including MAOIs), antipsychotics and other dopamine antagonists. SS symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Some signs of SS, including hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes resemble NMS. Patients should be monitored for the emergence of signs and symptoms of SS or NMS syndrome^{224,227} (see section **4.3. Contraindications**).

Monoamine Oxidase Inhibitors

Cases of serious reactions, sometimes fatal,¹⁹⁰ have been reported in patients receiving sertraline in combination with a MAOI, including the selective MAOI selegiline, the reversible MAOI moclobemide, and MAOI drugs, e.g., linezolid (an antibiotic that is a reversible non-selective MAOI) and methylene blue.^{220,231} Some cases presented with features resembling SS, the symptoms of which include hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma. Therefore, sertraline should not be used in combination with an MAOI or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should elapse after discontinuing sertraline treatment before starting an MAOI^{4,5,34,36,37} (see section **4.3. Contraindications**).

Other Serotonergic Drugs

Co-administration of sertraline with other drugs that enhance the effects of serotonergic neurotransmission, such as amphetamines,²⁴⁶ tryptophan, fenfluramine, and fentanyl, 5HT³⁸ agonists, or the herbal medicine St. John's Wort (*Hypericum perforatum*)²²² should be undertaken with caution and avoided whenever possible due to the potential for pharmacodynamic interaction.²¹⁰

QTc Prolongation/Torsade de Pointes (TdP)

Cases of QTc prolongation and TdP have been reported during post-marketing use of sertraline. The majority of reports occurred in patients with other risk factors for QTc prolongation/TdP. Therefore sertraline should be used with caution in patients with risk factors for QTc prolongation.(see sections **4.5. – Interaction with Other Medicinal Products and Other Forms of Interaction** and **5.1 – Pharmacodynamic Properties**).²³⁵

Switching from Selective Serotonin Reuptake Inhibitors, Antidepressants or Antiobsessional Drugs

There is limited controlled experience regarding the optimal timing of switching from SSRIs, antidepressants or anti-obsessional drugs to sertraline. Care and prudent medical judgment should be exercised when switching, particularly from long-acting agents such as fluoxetine. The duration of a washout period for switching from one SSRI to another has not been established.³³

Activation of Mania/Hypomania

During pre-marketing testing, hypomania or mania occurred in approximately 0.4% of sertraline-treated patients. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder treated with other marketed antidepressant and anti-obsessional drugs.³⁹

Seizures

Seizures are a potential risk with antidepressant and anti-obsessional drugs.⁴⁰ Seizures were reported in approximately 0.08% of patients treated with sertraline in the development program for depression.⁴¹ No seizures were reported in patients treated with sertraline in the development program for panic.¹⁷ During the development program for OCD, four out of approximately 1800 patients exposed to sertraline experienced seizures (approximately 0.2%).⁴² Three of these patients were adolescents, two with a seizure disorder and one with a family history of seizure disorder, none of whom were receiving anticonvulsant medication.⁴² In all these cases, the relationship with sertraline therapy was uncertain.⁴² Since sertraline has not been evaluated in patients with a seizure disorder, it should be avoided in patients with unstable epilepsy; patients with controlled epilepsy should be carefully monitored.⁴² Sertraline should be discontinued in any patient who develops seizures.⁴²

Suicide/Suicidal Thoughts or Clinical Worsening

All patients treated with sertraline, in particular those at high risk, should be monitored appropriately and observed closely for clinical worsening and suicidality. Patients, their families, and their caregivers should be encouraged to be alert to the need to monitor for any clinical worsening, suicidal behavior or thoughts and unusual changes in behavior especially when initiating therapy or during any change in dose or dosage regimen. The risk of suicide attempt must be considered, especially in depressed patients, and the smallest quantity of drug, consistent with good patient management, should be provided to reduce the risk of overdose.²³⁴

Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are strong predictors of suicide. Pooled analyses of short-term placebo-controlled trials of antidepressant medicines (SSRIs and others) showed that these medicines increase the risk of suicidality in children, adolescents, and young adults (aged 18 to 24 years) with major depression and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond the age of 24 years; there was a reduction in the risk of suicidality with antidepressants compared to placebo in adults aged 65 years and older.²³⁴

Sexual Dysfunction

Selective serotonin reuptake inhibitors (SSRIs) may cause symptoms of sexual dysfunction (see section **4.8. - Undesirable Effects**). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs.²⁴⁹

Abnormal Bleeding/Hemorrhage

There have been reports of bleeding abnormalities with SSRIs from ecchymoses and purpura to life-threatening hemorrhage.²³³ Caution is advised in patients taking SSRIs, particularly in concomitant use with drugs known to affect platelet function (e.g., atypical antipsychotics and phenothiazines, most tricyclic antidepressants, aspirin and non-steroidal anti-inflammatory drugs [NSAIDs]) as well as in patients with a history of bleeding disorders²²² (see section **4.5. Interaction with Other Medicinal Products and Other Forms of Interaction**).

Hyponatremia

Hyponatremia may occur as a result of treatment with SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs) including sertraline. In many cases, hyponatremia appears to be the result of a syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases of serum sodium levels lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk (see section **4.2. Posology and Method of Administration: Use in the Elderly**). Discontinuation of sertraline should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness and unsteadiness that may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.²²²

Because of the well-established comorbidity between OCD and depression, panic disorder and depression, PTSD and depression, and social phobia and depression,²¹⁵ the same precautions observed when treating patients with depression should be observed when treating patients with OCD, panic disorder, PTSD or social phobia.^{192,193,215}

Bone Fractures

Epidemiological studies show an increased risk of bone fractures in patients receiving serotonin reuptake inhibitors (SRIs) including sertraline. The mechanism leading to this risk is not fully understood.²³⁰

Use in Hepatic Insufficiency

Sertraline is extensively metabolized by the liver.^{43,44,45} A multiple-dose pharmacokinetic study in subjects with mild, stable cirrhosis demonstrated a prolonged elimination half-life and approximately

three-fold greater AUC and C_{\max} in comparison to normal subjects. There were no significant differences in plasma protein binding observed between the two groups.⁴⁶ The use of sertraline in patients with hepatic disease should be approached with caution. A lower or less frequent dose should be used in patients with hepatic impairment.³⁰

Use in Renal Insufficiency

Sertraline is extensively metabolized. Excretion of unchanged drug in urine is a minor route of elimination.³⁰ In studies of patients with mild to moderate renal impairment (creatinine clearance 30-60 mL/min) or moderate to severe renal impairment (creatinine clearance 10-29 mL/min), multiple-dose pharmacokinetic parameters (AUC_{0-24} or C_{\max}) were not significantly different compared to controls. Half-lives were similar, and there were no differences in plasma protein binding in all groups studied. This study indicates that, as expected from the low renal excretion of sertraline, sertraline dosing does not have to be adjusted based on the degree of renal impairment.³²

Diabetes/Loss of Glycemic Control

Cases of new-onset diabetes mellitus have been reported in patients receiving SSRIs including ZOLOFT®. Loss of glycemic control including both hyperglycemia and hypoglycemia has also been reported in patients with and without pre-existing diabetes. Patients should therefore be monitored for signs and symptoms of glucose fluctuations. Diabetic patients especially should have their glycemic control carefully monitored since their dosage of insulin and/or concomitant oral hypoglycemic drug may need to be adjusted.²²⁷

Laboratory Tests

False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking sertraline. This is due to lack of specificity of the screening tests. False-positive test results may be expected for several days following discontinuation of sertraline therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish sertraline from benzodiazepines.²²⁸

Angle-closure Glaucoma

SSRIs including sertraline may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle, resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Sertraline should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.²²⁹

Use in Children and Adolescents

Long-term safety on cognitive, emotional, physical, and pubertal maturation in children and adolescents aged 6 to 16 years was evaluated in a long-term observational study for up to 3 years (see section **5.1. – Pharmacodynamic Properties**).²⁵² Physicians must monitor pediatric patients on long-term treatment for abnormalities in growth and development.²³⁶

4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Monoamine Oxidase Inhibitors

See sections **4.3. Contraindications** and **4.4. Special Warnings and Precautions for Use**.

Pimozide

Increased pimozide levels have been demonstrated in a study of a single low-dose pimozide (2 mg) with sertraline co-administration.²¹⁷ These increased levels were not associated with any changes in electrocardiogram (EKG).²¹⁷ While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide, concomitant administration of sertraline and pimozide is contraindicated.²¹⁷

Sertraline Oral Concentrate and Disulfiram

As long as serum levels of disulfiram persist, or the activity of acetaldehyde dehydrogenase is diminished, ethanol ingestion will result in an adverse reaction. Depending on hepatic function, this effect may still be present for as long as two weeks after the last dose, although one week is the more typical duration of action with standard doses. Therefore, sertraline oral concentrate should not be used in combination with disulfiram or within 14 days of discontinuing treatment with disulfiram³⁵ (see sections **4.3. Contraindications** and **4.4. Special Warnings and Precautions for Use**).

Drugs that Prolong the QTc Interval

The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with concomitant use of other drugs that prolong the QTc interval (e.g., some antipsychotics and antibiotics)²³⁵ (see sections **4.4. Special Warnings and Precautions for Use** and **5.1 – Pharmacodynamic Properties**).

CNS Depressants and Alcohol

The co-administration of sertraline 200 mg daily did not potentiate the effects of alcohol, carbamazepine, haloperidol or phenytoin on cognitive and psychomotor performance in healthy subjects; however, the concomitant use of sertraline and alcohol is not recommended.^{47,48,49,50}

Lithium

In placebo-controlled trials in normal volunteers, the co-administration of sertraline with lithium did not significantly alter lithium pharmacokinetics, but did result in an increase in tremor relative to placebo, indicating a possible pharmacodynamic interaction. When co-administering sertraline with medications, such as lithium, which may act via serotonergic mechanisms, patients should be appropriately monitored.^{51,52}

Phenytoin

A placebo-controlled trial in normal volunteers suggests that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy, with appropriate adjustments to the phenytoin dose.^{50,53} In addition, co-administration of phenytoin may cause a reduction of sertraline plasma levels.²¹⁸

Sumatriptan

There have been rare post-marketing reports describing patients with weakness, hyperreflexia, incoordination, confusion, anxiety and agitation following the use of sertraline and sumatriptan. If concomitant treatment with sertraline and sumatriptan is clinically warranted, appropriate observation of the patient is advised³⁸ (see section 4.4. **Special Warnings and Precautions for Use: Other Serotonergic Drugs**).

Other Serotonergic Drugs

See section 4.4. **Special Warnings and Precautions for Use: Serotonin Syndrome, Monoamine Oxidase Inhibitors, and Other Serotonergic Drugs**

Protein-Bound Drugs

Since sertraline is bound to plasma proteins, the potential of sertraline to interact with other plasma protein-bound drugs should be borne in mind.³³ However, in three formal interaction studies with diazepam,⁵⁴ tolbutamide⁵⁵ and warfarin,⁵⁶ respectively, sertraline was not shown to have significant effects on the protein binding of the substrate (see subsections Warfarin and Other Drug Interactions).

Warfarin

Co-administration of sertraline 200 mg daily with warfarin resulted in a small but statistically significant increase in prothrombin time, the clinical significance of which is unknown. Accordingly, prothrombin time should be carefully monitored when sertraline therapy is initiated or stopped.^{57,58}

Other Drug Interactions

Formal drug interaction studies have been performed with sertraline. Co-administration of sertraline 200 mg daily with diazepam or tolbutamide resulted in small, statistically significant changes in some pharmacokinetic parameters.^{59,60,61,62} Co-administration with cimetidine caused a substantial decrease in sertraline clearance. The clinical significance of these changes is unknown.⁶³ Sertraline had no effect on the beta-adrenergic blocking ability of atenolol.⁶⁴ No interaction of sertraline 200 mg daily was observed with glibenclamide^{61,65} or digoxin.^{66,67,68}

Electroconvulsive Therapy

There are no clinical studies establishing the risks or benefits of the combined use of electroconvulsive therapy (ECT) and sertraline.

Drugs Metabolized by Cytochrome P450 2D6

There is variability among antidepressants in the extent to which they inhibit the activity of isozyme cytochrome P450 (CYP) 2D6. The clinical significance of this depends on the extent of inhibition and the therapeutic index of the co-administered drug. CYP 2D6 substrates with a narrow therapeutic index include tricyclic antidepressants (TCAs) and class 1C antiarrhythmics such as propafenone and flecainide. In formal interaction studies, chronic dosing with sertraline 50 mg daily showed minimal elevation (mean 23% to 37%) of steady-state desipramine plasma levels (a marker of CYP 2D6 isoenzyme activity).^{69,70,71,72}

Drugs Metabolized by Other CYP Enzymes (CYP 3A3/4, CYP 2C9, CYP 2C19, CYP 1A2)

CYP 3A3/4

In vivo interaction studies have demonstrated that chronic administration of sertraline 200 mg daily does not inhibit the CYP 3A3/4-mediated 6- β hydroxylation of endogenous cortisol⁷³ or the metabolism of carbamazepine⁷⁴ or terfenadine.⁷⁵ In addition, the chronic administration of sertraline 50 mg daily does not inhibit the CYP 3A3/4-mediated metabolism of alprazolam.⁷⁶ The data suggest that sertraline is not a clinically relevant inhibitor of CYP 3A3/4.

CYP 2C9

The apparent lack of clinically significant effects of the chronic administration of sertraline 200 mg daily on plasma concentrations of tolbutamide,⁵⁵ phenytoin⁷⁷ and warfarin^{56,57,58} suggests that sertraline is not a clinically relevant inhibitor of CYP 2C9 (see subsections Other Drug Interactions, Phenytoin, and Warfarin).

CYP 2C19

The apparent lack of clinically significant effects of the chronic administration of sertraline 200 mg daily on plasma concentrations of diazepam suggests that sertraline is not a clinically relevant inhibitor of CYP 2C19⁵⁴ (see subsection Other Drug Interactions).

CYP 1A2

In vitro studies indicate that sertraline has little or no potential to inhibit CYP 1A2.^{78,79}

4.6. FERTILITY, PREGNANCY AND LACTATION

Pregnancy

Reproduction studies have been performed in rats and rabbits at doses up to approximately 20 times and 10 times the maximum daily human mg/kg dose, respectively.^{80,81,82,83,84} There was no evidence of teratogenicity at any dose level.^{80,81,82,83,84} At the dose level corresponding to approximately 2.5 to 10 times the maximum daily human mg/kg dose, however, sertraline was associated with delayed ossification in fetuses, probably secondary to effects on the dams.^{82,83}

Observational studies have provided evidence of an increased risk (less than 2-fold) of postpartum haemorrhage following exposure to SSRIs, including sertraline, especially within the month prior to birth.²⁵¹

There was decreased neonatal survival following maternal administration of sertraline at doses approximately five times the maximum daily human mg/kg dose.^{85,86} Similar effects on neonatal survival have been described for other antidepressant drugs. The clinical significance of these effects is unknown.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, sertraline should be used during pregnancy only if the perceived benefits outweigh the risks.³³

If sertraline is used during pregnancy and/or lactation, the physician should be aware that symptoms, including those compatible with withdrawal reactions, have been reported in some neonates whose

mothers had been on SSRI antidepressants, including sertraline.^{90,91,92,93,94,95}

Women of childbearing potential should employ an adequate method of contraception if taking sertraline.³³

Exposure during late pregnancy to SSRIs may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1 to 2 per 1000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy.²²¹ A study of 831,324 infants born in Sweden in 1997 to 2005 found a PPHN risk ratio of 2.4 (95% CI, 1.2 to 4.3) associated with patient-reported maternal use of SSRIs “in early pregnancy” and a PPHN risk ratio of 3.6 (95% CI, 1.2 to 8.3) associated with a combination of patient-reported maternal use of SSRIs “in early pregnancy” and an antenatal SSRI prescription “in later pregnancy”.^{225,226}

Lactation

Isolated studies in small numbers of nursing mothers and their infants indicated negligible or undetectable levels of sertraline in infant serum, although levels in breast milk were more concentrated than in maternal serum. Use in nursing mothers is not recommended unless, in the judgment of the physician, the benefits outweigh the risks.^{33,87,88,89}

Fertility

There is no clinical trial data on fertility. In animal studies, no effect on fertility parameters was observed^{238, 243} (see also section 5.3. Preclinical Safety Data).

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Clinical pharmacology studies have shown that sertraline has no effect on psychomotor performance.^{47,96,97} However, as psychotropic drugs may impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, the patient should be cautioned accordingly.³³

4.8. UNDESIRABLE EFFECTS

The side-effect profile commonly observed in double-blind, placebo-controlled studies in patients with OCD,⁹⁸ panic disorder,¹⁰⁰ PTSD, and social phobia²¹⁵ was similar to that observed in clinical trials in patients with depression.^{98,100}

Adverse Drug Reaction Table	
System Organ Class	Adverse Drug Reactions
Blood and lymphatic system disorders	thrombocytopenia ^{*§131,133} , leukopenia ^{*§132} , platelet function test abnormal ^{*§131}
Immune system disorders	anaphylactoid reaction ^{*§166} , hypersensitivity ^{*103,211}
Endocrine disorders	inappropriate antidiuretic hormone secretion ^{*§173} , hyperprolactinaemia ^{*§127} , hypothyroidism ^{*128}
Metabolism and nutrition disorders	diabetes mellitus ^{*227} , hyponatraemia ^{*§135} , hypoglycaemia ^{*227} , hyperglycaemia ^{*§227} , decreased appetite ^{11,98,99} , increased appetite ^{*174}

Adverse Drug Reaction Table	
System Organ Class	Adverse Drug Reactions
Psychiatric disorders	psychotic disorder ^{*142} , hallucination ^{*141} , aggression ^{*138} , confusional state ^{*124,125} , euphoric mood ^{*178} , depressive symptoms ^{*140} , anxiety ^{*139} , agitation ^{*137} , bruxism ^{*121} , nightmare ^{*181} , libido decreased ^{*179,180} , insomnia ^{11,98,99}
Nervous system disorders	serotonin syndrome ^{*§124,125} , coma ^{*114} , convulsion ^{*§115} , dystonia ^{*§229} , akathisia ^{*229} , syncope ^{*112} , extrapyramidal disorder ^{*118,119,120,121,229} , muscle contractions involuntary ^{*171} , hypoaesthesia ^{*123} , hyperkinesia ^{*119} , migraine ^{*117} , hypertonia ^{*120,219} , tremor ^{11,98,99} , somnolence ^{11,98,99} , paraesthesia ^{*122} , dizziness ^{11,98,99} , headache ^{*116}
Eye disorders	visual impairment ^{*189} , mydriasis ^{*101} , periorbital oedema ^{*111}
Ear and labyrinth disorders	tinnitus ^{*176}
Cardiac disorders	torsade de pointes ^{*§235} (see sections 4.4. Special Warnings and Precautions for Use , 4.5. Interaction with Other Medicinal Products and Other Forms of Interaction and 5.1. Pharmacodynamic Properties), electrocardiogram QT prolonged ^{*235} (see sections 4.4. Special Warnings and Precautions for Use , 4.5. Interaction with Other Medicinal Products and Other Forms of Interaction and 5.1. Pharmacodynamic Properties), blood cholesterol increased ^{*§136} , palpitations ^{*110} , tachycardia ^{*113}
Vascular disorders	cerebral vasoconstriction ^{*§229} (including reversible cerebral vasoconstriction syndrome and Call-Fleming syndrome), haemorrhage ^{*131} , hypertension ^{*109} , hot flush ^{*107}
Respiratory, thoracic and mediastinal disorders	bronchospasm ^{*144} , epistaxis ^{*131} , yawning ^{*182}
Gastrointestinal disorders	gastrointestinal haemorrhage ^{*131} , pancreatitis ^{*§130} , diarrhoea ^{11,98,99} , nausea ^{11,98,99} , vomiting ^{*129} , constipation ^{*175} , abdominal pain ^{*129} , dry mouth ^{11,98,99} , dyspepsia ^{11,98,99}
Hepatobiliary disorders	liver injury ^{*§134} , alanine aminotransferase increased ^{*134} , aspartate aminotransferase increased ^{*134}
Skin and subcutaneous tissue disorders	toxic epidermal necrolysis ^{*§186} , Stevens-Johnson syndrome ^{*§185} , angioedema ^{*§146} , exfoliative rash ^{*§191} , photosensitivity skin reaction ^{*§183} , urticaria ^{*187} , purpura ^{*129} , pruritus ^{*184} , alopecia ^{*145} , rash ^{*147} , hyperhidrosis ^{11,98,99}
Musculoskeletal and connective tissue disorders	rhabdomyolysis ^{*§245,248} , trismus ^{*§244} , muscle spasms ^{*219} , arthralgia ^{*177}
Renal and urinary disorders	urinary retention ^{*149} , haematuria ^{*131} , urinary incontinence ^{*188} , enuresis ^{*§223}
Reproductive system and breast disorders	priapism ^{*102} , galactorrhoea ^{*126} , gynaecomastia ^{*172} , ejaculation disorder ^{11,98,99} , sexual dysfunction ^{11,98,99} (see section 4.4. Special Warnings and Precautions for Use), menstruation irregular ^{*143}
General disorders and administration site conditions	face oedema ^{*148} , drug withdrawal syndrome ^{*§150} , gait disturbance ^{*118} , oedema peripheral ^{*170} , chest pain ^{*108} , malaise ^{*167} , pyrexia ^{*106} , asthenia ^{*104} , fatigue ^{*105}
Investigations	weight decreased ^{*168} , weight increased ^{*169} , laboratory test abnormal ^{*129}
Injury, poisoning and procedural complications	fracture ^{*230}

*ADR identified post-marketing

§ ADR frequency represented by the estimated upper limit of the 95% confidence interval calculated using "The Rule of 3".

4.9. OVERDOSE

Sertraline has a margin of safety dependent on patient population and/or concomitant medications. Deaths have been reported involving overdoses of sertraline, alone or in combination with other drugs and/or alcohol.²³² Therefore, any overdosage should be treated aggressively.¹⁵² Symptoms of overdose include serotonin-mediated side effects such as electrocardiogram QT prolonged, TdP,²³⁵ (see sections **4.4 - Special Warnings and Precautions for Use, 4.5 - Interactions with Other Medicinal Products and Other Forms of Interaction and 5.1 – Pharmacodynamic Properties**) somnolence, gastrointestinal disturbances (such as nausea and vomiting), tachycardia, tremor, agitation and dizziness. Less frequently reported was coma.^{153,232}

There are no specific antidotes to sertraline. Establish and maintain an airway and ensure adequate oxygenation and ventilation, if necessary. Activated charcoal, which may be used with a cathartic, may be as or more effective than lavage, and should be considered in treating overdose. Induction of emesis is not recommended. Cardiac and vital sign monitoring is recommended, along with general symptomatic and supportive measures. Due to the large volume of distribution of sertraline, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit.^{241,242}

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Sertraline is a potent and selective inhibitor of neuronal serotonin (5-HT) reuptake *in vitro*, which results in the potentiation of the effects of 5-HT in animals.^{154,155,194} It has only very weak effects on norepinephrine and dopamine neuronal reuptake.^{154,200} At clinical doses, sertraline blocks the uptake of serotonin into human platelets.¹⁹⁵ It is devoid of stimulant, sedative or anticholinergic activity or cardiotoxicity in animals.^{154,155} In controlled studies in normal volunteers, sertraline did not cause sedation and did not interfere with psychomotor performance.⁹⁶ In accord with its selective inhibition of 5-HT uptake, sertraline does not enhance catecholaminergic activity.^{154,155,196} Sertraline has no affinity for muscarinic (cholinergic), serotonergic, dopaminergic, adrenergic, histaminergic, gamma-aminobutyric acid (GABA) or benzodiazepine receptors.^{154,197} The chronic administration of sertraline in animals was associated with down-regulation of brain norepinephrine receptors as observed with other clinically effective antidepressants and anti-obsessional drugs.^{154,198,199}

Sertraline has not demonstrated potential for abuse. In a placebo-controlled, double-blind, randomized study of the comparative abuse liability of sertraline, alprazolam and d-amphetamine in humans, sertraline did not produce positive subjective effects indicative of abuse potential. In contrast, subjects rated both alprazolam and d-amphetamine significantly greater than placebo on measures of drug liking, euphoria and abuse potential. Sertraline did not produce either the stimulation and anxiety associated with d-amphetamine or the sedation and psychomotor impairment associated with alprazolam. Sertraline does not function as a positive reinforcer in rhesus monkeys trained to self-administer cocaine, nor does it substitute as a discriminative stimulus for either d-amphetamine or pentobarbital in rhesus monkeys.^{157,158}

Clinical Trials

Major Depressive Disorder

A study was conducted that involved depressed outpatients who had responded by the end of an initial 8-week open treatment phase on sertraline 50 mg/day to 200 mg/day.²²⁰ These patients (N=295) were randomized to continuation for 44 weeks on double-blind sertraline 50 mg/day to 200 mg/day or placebo.²²⁰ A statistically significantly lower relapse rate was observed for patients taking sertraline

compared to those on placebo.²²⁰ The mean dose for completers was 70 mg/day.²²⁰

Obsessive-Compulsive Disorder

In a long-term study, patients meeting DSM-III-R criteria for OCD who had responded during a 52-week single-blind trial on sertraline 50 mg/day to 200 mg/day (n=224) were randomized to continuation of sertraline or to substitution of placebo for up to 28 weeks of observation for discontinuation due to relapse or insufficient clinical response.²¹² Patients receiving continued sertraline treatment experienced a significantly lower rate of discontinuation due to relapse or insufficient clinical response over the subsequent 28 weeks compared to those receiving placebo.²¹² This pattern was demonstrated in male and female subjects.²¹²

Panic Disorder

In a long-term study, patients meeting DSM-III-R criteria for panic disorder who had responded during a 52-week open trial on sertraline 50 mg/day to 200 mg/day (n=183) were randomized to continuation of sertraline or to substitution of placebo for up to 28 weeks of observation for discontinuation due to relapse or insufficient clinical response.²¹³ Patients receiving continued sertraline treatment experienced a significantly lower rate of discontinuation due to relapse or insufficient clinical response over the subsequent 28 weeks compared to those receiving placebo.²¹³ This pattern was demonstrated in male and female subjects.²¹³

Post-traumatic Stress Disorder

In a long-term study, patients meeting DSM-III-R criteria for PTSD who had responded during a 24-week open trial on sertraline 50 mg/day to 200 mg/day (n=96) were randomized to continuation of sertraline or to substitution of placebo for up to 28 weeks of observation for relapse.²¹⁴ Patients receiving continued sertraline treatment experienced significantly lower relapse rates over the subsequent 28 weeks compared to those receiving placebo.²¹⁴ This pattern was demonstrated in male and female subjects.²¹⁴

Social Phobia (Social Anxiety Disorder)

In a social phobia relapse prevention study, patients who were responders at the end of a 20-week, multicenter, flexible-dose study that compared sertraline (50 mg/day to 200 mg/day) to placebo were re-randomized for an additional 24 weeks to either sertraline continuation treatment (within 50 mg/day to 200 mg/day) or placebo substitution, while placebo responders remained on placebo.²¹⁶ Patients receiving sertraline continuation treatment experienced a statistically significantly lower relapse rate over this 24-week study than patients randomized to placebo substitution treatment.²¹⁶

Cardiac Electrophysiology

In a dedicated thorough QTc study, conducted at steady-state at supratherapeutic exposures in healthy volunteers (treated with 400 mg/day, twice the maximum recommended daily dose), the upper bound of the 2-sided 90% CI for the time matched Least Square mean difference of QTcF between sertraline and placebo (11.666 msec) was greater than the predefined threshold of 10 msec at the 4-hour postdose time point. Exposure-response analysis indicated a slightly positive relationship between QTcF and sertraline plasma concentrations [0.036 msec/(ng/mL); $p < 0.0001$]. Based on the exposure-response model, the threshold for clinically significant prolongation of the QTcF (i.e., for predicted 90% CI to exceed 10 msec) is at least 2.6-fold greater than the average C_{max} (86 ng/mL) following the highest recommended dose of sertraline (200 mg/day) (see sections **4.4. - Special warnings and precautions for Use, 4.5. -**

Interactions with Other Medicinal Products and Other Forms of Interaction, 4.8. - Undesirable Effects and 4.9 - Overdose).²⁴⁷Pediatric PopulationPost-marketing safety study SPRITES

An observational post-approval study of 941 patients aged 6 to 16 years was conducted to evaluate the long-term safety of treatment with sertraline (with and without psychotherapy) compared with psychotherapy on cognitive, emotional, physical, and pubertal maturation for up to 3 years. This study was conducted in clinical practice settings in children and adolescents with primary diagnoses of obsessive compulsive disorder, depression, or other anxiety disorders and evaluated cognition [assessed by the Trails B test and the Metacognition Index from the Behavior Rating Inventory of Executive Function (BRIEF), behavioral/emotional regulation (assessed by the Behavioral Regulation Index from the BRIEF) and physical/pubertal maturation (assessed by standardized height/weight/body mass index (BMI) and Tanner Stage)]. Sertraline is approved in the pediatric population only for patients aged 6 years of age and older with OCD (see section 4.1. - **Therapeutic Indications**).²⁵²

Standardization of each primary outcome measure based on sex and age norms showed that the overall results were consistent with normal development. No statistically significant differences were observed for the primary outcome measures, with the exception of weight. A statistically significant finding for standardized weight was observed in comparative analyses; however, the magnitude of the change in weight was small [mean (SD) change in standardized z-scores <0.5 SD] and observed mainly at higher doses.²⁵²

5.2. PHARMACOKINETIC PROPERTIES

Sertraline exhibits dose-proportional pharmacokinetics over the range of 50 mg to 200 mg.¹⁵⁹ In man, following oral once-daily dosing over the range of 50 mg to 200 mg for 14 days, peak plasma concentrations (C_{max}) of sertraline occur at about 4.5 to 8.4 hours post-dosing.^{160,161,162,201,202} The pharmacokinetic profile in either adolescents or the elderly is not significantly different from that in adults between 18 and 65 years.²⁵ The mean half-life of sertraline for young and elderly men and women ranges from 22 to 36 hours.^{161,202,203,204} Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation up to steady-state concentrations, which are achieved after one week of once-daily dosing.^{159,161} Approximately 98% of the circulating drug is bound to plasma proteins.²⁰⁵ Animal studies indicate that sertraline has a large apparent volume of distribution.¹⁵⁹ The pharmacokinetics of sertraline in pediatric OCD patients have been shown to be comparable to adults (although pediatric patients metabolize sertraline with slightly greater efficiency).¹⁶ However, lower doses may be advisable for pediatric patients, given their lower body weights (especially those patients aged 6 to 12 years), in order to avoid excessive plasma levels.¹⁶

Sertraline undergoes extensive first-pass hepatic metabolism.¹⁵⁹ The principal metabolite in plasma, N-desmethylsertraline, is substantially less active (about 20 times) than sertraline *in vitro*, and there is no evidence of activity in *in vivo* models of depression.^{206,207} The half-life of N-desmethylsertraline is in the range of 62 to 104 hours.^{161,204} Sertraline and N-desmethylsertraline are both extensively metabolized in man and the resultant metabolites excreted in feces and urine in equal amounts.^{162,208} Only a small amount (<0.2%) of unchanged sertraline is excreted in urine.^{161,202,209}

Since the bioavailability of sertraline capsules is increased in the presence of food, it is recommended that sertraline capsules be administered with meals.¹³

Food does not significantly change the bioavailability of sertraline tablets and oral concentrate.^{3,163}

5.3. PRECLINICAL SAFETY DATA

Extensive chronic safety evaluation studies in animals show that sertraline is generally well tolerated at doses that are appreciable multiples of those that are clinically effective.¹² Sertraline has also been shown to be devoid of mutagenic effects.¹²

Juvenile Animal Studies

In a juvenile toxicology study in Sprague-Dawley rats, dose levels of 0, 10, 40 or 80 mg/kg/day of sertraline were administered orally to male and female rats on post-natal Days 21 through 56, with a non-dosing recovery phase up to post-natal Day 196. The administration of 80 mg/kg of sertraline to males and females on post-natal Days 21 to 56 resulted in dehydration, chromorhinorrhea and reduced average body weight gain. In addition, rales, hunched posture and reduced food consumption also occurred in male rats given 80 mg/kg/day. Delays in sexual maturation occurred in males (80 mg/kg/day) and females (≥ 10 mg/kg/day), but despite this finding there were no sertraline-related effects on any of the male (organ weights, mating and fertility, sperm motility or sperm concentration) or female (estrous cycling, mating and fertility, or ovarian and uterine parameters) reproductive endpoints that were assessed. There were no sertraline-related effects on any behavior parameter (learning and memory, auditory startle response, and locomotor activity) in males, while a decrease in auditory startle response occurred in females at 40 and 80 mg/kg/day. There were no sertraline-related effects on male or female femur lengths, brain weights, gross necropsy or microscopic observations at any dose level. In juvenile males, the no-observed-adverse-effect level (NOAEL) for general toxicity was 40 mg/kg/day (correlating to a C_{max} of 262 ng/mL and an AUC_{0-t} of 3170 ng·hr/mL on post-natal Day 56). In juvenile females, the NOAEL could not be established based on the delays in sexual maturation that occurred at ≥ 10 mg/kg. All of the aforementioned effects attributed to the administration of sertraline were reversed at some point during the non-dosing recovery phase of the study. The clinical relevance of these effects observed in rats administered sertraline has not been established.²³⁶

Animal Studies on Fertility

In two studies conducted in rats, collective evidence did not show an effect on fertility parameters.^{238,243}

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

Sertraline tablets include the following inert ingredients: calcium hydrogen phosphate, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, hydroxypropylmethyl cellulose, polyethylene glycol, polysorbates and titanium dioxide (E171).²

6.2. INCOMPATIBILITIES

Not available.

6.3. SHELF LIFE

24 months

6.4. SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

Avoid exposure to heat, sunlight and moisture.

6.5. NATURE AND CONTENTS OF CONTAINER

ZOLOFT® (sertraline) 50mg and 100 mg tablet are available in Transparent PVDC Aluminum blister.

Excipients:

Film-coated Tablet:

Calcium Hydrogen Phosphate
Hydroxypropyl Cellulose
Hydroxypropylmethyl Cellulose
Magnesium Stearate
Microcrystalline Cellulose
Polyethylene Glycol
Polysorbates
Sodium Starch Glycolate
Titanium Dioxide (E171)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors (see section 4.4. Special Warnings and Precautions for Use).

Zoloft/LPD/PK-09

According to CDS V 26, Dated: 03 May 2021; Supersedes CDS V 25, Dated: 02 Apr 2021

Marketed by:
Pfizer Pakistan Limited

Please visit our website www.pfizerpro.com.pk for latest version of Product leaflet.

7. REFERENCES

1. Sertraline HCL Capsules IRD, Sept. 1988, Vol. 2.1, Part IIA (Complete Qualitative and Quantitative Composition), pp. 3-17.
2. Sertraline HCL Tablets IRD, Sept. 1988, Vol. 2.1, Part IIA (Complete Qualitative and Quantitative Composition), pp. 3-17.
3. Sertraline Oral Concentrate IRD, Feb. 1999.
4. *Protocol 050-104*: Double-blind, multisite comparison of sertraline, amitriptyline, and placebo in the treatment of patients with major depression. Sertraline IRD Vol. 5.6, Sept. 1988.
5. *Protocol 050-103*: A double-blind, multisite comparison of three fixed daily doses of sertraline and placebo in the treatment of patients with major depression. Sertraline IRD Vol. 5.5, Sept. 1988.
6. *Protocol 050-105*: Double-blind, multicenter comparison of sertraline and amitriptyline in the treatment of geriatric patients with major depression. Sertraline IRD Vol. 5.10, Sept. 1988.
7. Clinical Expert Report on the Use of Sertraline in Reducing Concomitant Anxiety in Patients with Depression with Anxiety: Lustral Application to Vary a License, Approved by the United Kingdom Medicine Central Agency, Oct. 1994.
8. Fontaine R *et al.* "The Efficacy and Safety of Sertraline Versus Imipramine in Outpatients with Major Depression: A six-month, double-blind, parallel multicenter study." *Euro Neuropsychopharmacol*, 1991;1(3): 447.
9. Fontaine R *et al.* *The Efficacy and Safety of Sertraline Versus Imipramine in Outpatients with Major Depression: A six-month, double-blind, parallel multicenter study.* Poster presented at IVth ECNP Congress, Monte Carlo, Monaco, Oct. 6-9, 1991.
10. Doogan DP and Caillard V. "Sertraline in the Prevention of Relapse in Major Depression." Abstract 31.02.116, *Psychopharmacology*, Sept. 1988;96(suppl): 271.
11. Gunn KP *et al.* *Sertraline in the Long-term Treatment of Depression.* Eur Coll Neuropsychopharm (Abstracts): Gothenburg, Sweden, May 23-26, 1989.
12. Sertraline OCD IRD, Feb. 1994.
13. *Protocol 216*: A single dose study to determine the effect of food on the bioavailability of sertraline in healthy volunteers. Sertraline HCl IRD, Vol. 5.2, Sept. 1988, p. 231-262.
14. Rasmussen S *et al.* *Long-term Sertraline in the Treatment of Obsessive-Compulsive Disorder: A two-year study.* Poster presented at VIIIth Eur Coll Neuropsychopharm, Venice, Italy, Sept. 30-Oct. 4, 1995.
15. *Protocol 90CE21-0494*: Abstract of Final Study Report: Open follow-up study of sertraline in outpatients with Obsessive-Compulsive Disorder, May 2, 1995.
16. Sertraline Pediatric OCD IRD, Sept. 5, 1997.

17. Sertraline Panic Disorder IRD, Sept. 1996.
18. *Protocol 050-021*: A Phase I study to compare the pharmacokinetics of sertraline administered as a 100 mg tablet in the morning and evening with that of a 100 mg capsule administered in the morning in normal, healthy male volunteers, Sept. 1994. (Vol. 6: Bioequivalence/Bioavailability Studies.)
19. *Protocol 050-022*: A Phase I study to compare the pharmacokinetics of a single 100 mg oral dose of sertraline administered as a tablet under fasting and non-fasting conditions with that of a capsule administered under non-fasting conditions in normal, healthy male volunteers, Sept. 1994. (Vol. 9: Interaction Studies.)
20. Thompson C and Lane R. *Sertraline 50 mg: Optimal Dose in Depression*. Poster presented at XIXth CINP Congress, Washington, DC, June 27-July 1, 1994.
21. Preskorn SH and Lane RM. "Sertraline 50 mg Daily—the optimal dose in the treatment of depression." *Int Clin Psychopharmacol*, Dec. 6, 1994.
22. *Protocol 050-105*: Double-blind, multicenter comparison of sertraline and amitriptyline in the treatment of geriatric patients with major depression, Sept. 1994. (Vol. 25.)
23. *Protocol 050-320*: A multicenter, long-term comparative study of sertraline in depression, Sept. 1994. (Vol. 16.)
24. Reimher FW. "Sertraline, a selective inhibitor of serotonin uptake for the treatment of outpatients with major depressive disorder." *Psychopharm Bull*, 1988;24(9): 200-205.
25. Alderman J *et al*. *Sertraline Treatment in Children and Adolescents: Tolerability, Efficacy and Pharmacokinetics*. Poster presented at XXth CINP Congress, Melbourne, Australia, June 23-27, 1996.
26. Cohn CK *et al*. "Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients." *J Clin Psych*, 1990;51: 28-33.
27. Finkel SI. "Efficacy and tolerability of antidepressant therapy in the old-old." *J Clin Psych* 1996;57(suppl 5): 23-28.
28. Linden RD *et al*. *SSRIs in the depressed elderly: A double-blind comparison of sertraline and fluoxetine in depressed geriatric outpatients*. Abstract presented at the CXLVIIIth Annual Meeting of the APA, Miami, FL, May 20-25, 1995.
29. McEntee WJ *et al*. *A double-blind comparison of sertraline and nortriptyline in the treatment of depressed geriatric outpatients*. Poster presented at the CXLVIIIth Annual Meeting of the APA, Miami, FL, May 20-25, 1995.
30. Sertraline Capsules IRD, Expert Clinical Evaluation, Part IV, Vol. 1, pp. 5, 47-48.
31. *Protocol 050-025*: Phase I multiple-dose study to compare the safety and disposition of sertraline and desmethylsertraline in normal volunteers to subjects with varying degrees of renal insufficiency. Final report, April 22, 1998.

32. Wilner KD *et al.* *Multiple-dose pharmacokinetics of subjects with varying degrees of renal impairment.* Poster presented at XXth CINP Congress, Melbourne, Australia, June 23-27, 1996.
33. Standard medical practice.
34. Sertraline and MAOIs, Clinical Safety Report, Nov. 30, 1993.
35. Goldfrank LR, Flomenbaum NE, Lewin NA *et al.* "What is the metabolic basis of the disulfiram reaction?" *Goldfrank's Toxicological Emergencies*, 5th ed. Appleton & Lange; Norwalk, CT, 1994: 900-902.
36. Sertraline and Selegiline/Moclobemide, Safety Evaluation & Epidemiology, Apr. 5, 1995.
37. Lane R and Fischler B. "The Serotonin Syndrome: Co-administration, discontinuation and washout periods for selective serotonin reuptake inhibitors (SSRIs)." *J Serotonin Res*, 1995;3:171-180.
38. Worldwide Labeling Safety Report: Sertraline and Sumatriptan Drug Interaction, June 7, 1999.
39. Henry EW *et al.* *Assessment of manic reactions during treatment with SSRI sertraline: Does this afford patient benefit?* Poster presented at the IXth World Congress of Psychiatry, Rio de Janeiro, Brazil, June 6-12, 1993.
40. Henry EW *et al.* *Analysis of seizure potential in the sertraline, placebo and active groups in the sertraline development program.* Poster presented at the IXth World Congress of Psychiatry, Rio de Janeiro, Brazil, June 6-12, 1993.
41. Sertraline Capsules IRD II, Sept. 1994, Part IV, Vol. 2, pp. 514-515.
42. Sertraline OCD, Final Safety Update filed to the FDA, Dec. 7, 1995, Vol. I, Section 2, pp. 4-9.
43. *Study 8: Metabolism and excretion of [1-¹⁴C] sertraline in the rat.* Sertraline IRD, Vol. 4, Sept. 1988, pp. 246-261.
44. *Study 9: Metabolism and excretion of [1-¹⁴C] sertraline in the dog.* Sertraline IRD, Vol. 4, Sept. 1988, pp. 262-280.
45. *Protocol 050-225-136: An open study to compare the safety and pharmacokinetic profile of orally administered sertraline in patients with stable chronic hepatic insufficiency and in healthy subjects.*
46. Wilner KD *et al.* *Multiple-dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment.* Poster presented at the XXth CINP Congress, Melbourne, Australia, June 23-27, 1996.
47. Hindmarch I *et al.* "The effects of sertraline on psychomotor performance in elderly volunteers." *J Clin Psych*, 1990;51(12)(suppl B): 34-36.
48. *Protocol 050-226: A double-blind, placebo-controlled, parallel group study to investigate the effects of orally administered sertraline on the plasma-concentration profile of carbamazepine and its epoxide metabolite, and the cognitive effects of the two drugs in healthy volunteers.* (Vol. 13.)

49. *Protocol 050-227*: A double-blind, placebo-controlled, parallel group study to examine the effects of haloperidol alone and following multiple doses of sertraline on cognitive function and psychomotor tests in healthy male volunteers. (Vol. 13.)
50. *Protocol 050-228*: A double-blind, placebo-controlled, parallel group study to investigate the effects of orally administered sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. (Vol. 12.)
51. Sertraline and lithium pharmacokinetic drug interaction. Worldwide Safety Report, Dec. 23, 1997.
52. *Protocol 050-017*: A Phase I study to assess the potential of sertraline to alter the steady-state levels and renal clearance of lithium in healthy volunteers. (Vol. 12.)
53. Sertraline and phenytoin pharmacokinetic drug interaction. Worldwide Safety Report, Dec. 22, 1997.
54. Gardner MJ *et al.* "Effects of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers." *Clin Pharmacokinetics*, 1996(suppl T/C): 1-7.
55. Tremaine LM *et al.* "A study of the potential effects of sertraline on the pharmacokinetics and protein binding of tolbutamide." *Clin Pharmacokinetics*, 1996(suppl T/C): 1-7.
56. Wilner KD *et al.* "Effects of sertraline on the protein binding of warfarin." *Clin Pharmacokinetics*, 1996(suppl T/C): 1-7.
57. *Protocol 050-018*: A Phase I study to assess the potential of sertraline to alter the pharmacodynamic and plasma protein-binding of warfarin in healthy volunteers. (Vol. 11.)
58. *Protocol 050-211*: An open study of the potential for interaction between sertraline and warfarin in healthy male volunteers. (Vol. 11.)
59. *Protocol 050-016*: A Phase I study to assess the potential of sertraline to alter the pharmacokinetics of diazepam in healthy volunteers. (Vol. 10: Drug Interactions.)
60. *Protocol 050-206*: A double-blind, placebo-controlled crossover study to assess the effects of sertraline, along with diazepam, on psychomotor performance. (Vol. 10: Drug Interactions.)
61. Wilner KD. *Effects of sertraline on the pharmacokinetics of oral hypoglycemic agents in healthy volunteers*. Poster presented at IXth World Congress of Psychiatry, Rio de Janeiro, Brazil, June 6-12, 1993.
62. *Protocol 050-011*: A Phase I study to assess the potential of sertraline to alter the clearance or plasma protein-binding of tolbutamide in healthy volunteers. (Vol. 11.)
63. *Protocol 050-019*: A Phase I study to assess the potential of cimetidine to alter the disposition of sertraline in normal, healthy male volunteers. (Vol. 12.)
64. *Protocol 050-013*: A Phase I study to assess the potential of sertraline to alter the beta-adrenergic blocking activity of atenolol. (Vol. 12.)
65. *Protocol 050-223*: A double-blind, placebo-controlled, multiple-dose study to assess potential

- interactions between oral sertraline (200 mg) and glibenclamide (5 mg) in healthy male volunteers. (Vol. 12.)
66. *Protocol 050-224*: A double-blind, placebo-controlled, parallel group study to investigate the effects of orally administered sertraline in the plasma-concentration profile and renal clearance of digoxin. (Vol. 10: Drug Interactions.)
 67. *Protocol 050-204*: A double-blind, placebo-controlled, parallel group study to evaluate the potential for sertraline–digoxin interaction in healthy male volunteers. (Vol. 10: Drug Interactions.)
 68. *Protocol 050-219*: A double-blind, placebo-controlled, two-way crossover study of the effects of sertraline on the pharmacokinetic profile of digoxin in healthy male volunteers. (Vol. 10: Drug Interactions.)
 69. *Protocol R-0316*: Multiple-dose interaction study of desipramine (50 mg q.d.) with sertraline (50 mg q.d.) or paroxetine (20 mg q.d.) in healthy adult volunteers.
 70. Alderman J *et al.* *Desipramine pharmacokinetics with the serotonin reuptake inhibitors, paroxetine or sertraline.* Poster presented at XIXth CINP Congress, Washington, DC, June 24-July 1, 1994.
 71. Pharmacokinetics Study Report, Study No. 91-S-0704, *Protocol R-0228*: Multiple-dose interaction study of desipramine (50 mg q.d.) with sertraline (50 mg q.d.) or fluoxetine (20 mg q.d.) in healthy adult volunteers, Oct. 23-Dec. 26, 1991. (Vol. 9.)
 72. Preskorn SH *et al.* “Pharmacokinetics of desipramine co-administered with sertraline or fluoxetine.” *J Clin Psychopharmacol*, 1994;14(2): 90-98.
 73. Harvey A *et al.* “Sertraline and P450 3A3/4.” *Euro Psychopharmacol* 1996;6(suppl 3): 40.
 74. Rapeport WG *et al.* “Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.” *J Clin Psych* 1996;57(suppl 1): 20-23.
 75. Synopsis of Preliminary Summary Report, Sertraline Study No. 96-S-0504/*Protocol R-0498*: A multiple-dose study to determine the potential interaction of sertraline 200 mg/day with terfenadine in healthy subjects, July 30, 1996.
 76. Sertraline and alprazolam pharmacokinetic drug interaction. Worldwide Safety Report, Dec. 23, 1997.
 77. Rapeport WG *et al.* Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. *J Clin Psych*, 1996;57(suppl 1): 24-28.
 78. Brosen K *et al.* “Fluvoxamine as a potent inhibitor of cytochrome P450 1A2.” *Biochem Pharmacol*, 1993;6: 1211-1214.
 79. Rasmussen BB *et al.* “Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine.” *Br J Clin Pharmacol*, 1995; 39(2): 151-159.

80. *Protocol 79-375-06 & C9-375-06: A study of the reproduction and fertility of rats. Segment I (Extended to produce F₂ litters), Sept. 1988. (Vol. 3.4.)*
81. *Protocol 80142: Fetotoxicity and fertility study (FDA protocol, segment I) in rats by oral administration, Sept. 1988. (Vol. 3.4.)*
82. *Protocol 85121/85126: Fetotoxicity study in rats by oral route. Sertraline IRD, Vol. 3.4, Sept. 1988, p. 1062-1116.*
83. *Protocol 80107: Fetotoxicity study (FDA segment II) in rabbits by the oral route. Sertraline IRD, Vol. 3.4, Sept. 1988, p. 1117-1160.*
84. *Protocol 86-375-14: An exploratory oral gavage reproductive study in Sprague-Dawley rats, Sept. 1988. (Vol. 3.4.)*
85. *Protocol 83107: Peri- and post-natal development study in rats by the oral route, Sept. 1988. (Vol. 3.4.)*
86. *Protocol 83112: Peri- and post-natal development study in rats by the oral route, Sept. 1988. (Vol. 3.4.)*
87. Altshuler LL *et al.* "Breastfeeding and sertraline: A 24-hour analysis." *J Clin Psych*, 1995;56: 243-245.
88. Stowe ZN *et al.* *Excretion of sertraline in human breast milk.* Presented at the 24th North American Society for Psychosomatic Obstetrics and Gynecology, Santa Fe, NM, Feb. 28-March 3, 1995.
89. Winn SS *et al.* *Sertraline in breast milk and nursing infants.* New Research Program abstract presented at the CXLVIIIth Annual Meeting of the APA, Miami, FL, May 20-25, 1995.
90. Safety Evaluation & Epidemiology Report: Sertraline and Neonatal Withdrawal, Oct. 13, 1998.
91. Safety Evaluation & Epidemiology Report: Adverse events in neonates breastfeeding from sertraline-treated mothers, Oct. 8, 1998.
92. Wisner KL *et al.* "Serum sertraline and N-desmethylsertraline levels in breastfeeding mother-infant pairs." *Am J Psych*, 1998;155(5): 690-692.
93. Mammen OK *et al.* "Sertraline and norsertraline levels in three breastfed infants." *J Clin Psych*, 1997;58: 100-103.
94. Stowe ZN *et al.* "Sertraline and desmethylsertraline in human breast milk and nursing infants." *Am J Psych*, 1997;154(9): 1255-1260.
95. Sertraline and Dependence/Withdrawal Syndrome. Worldwide Safety Report, Feb. 18, 1998.
96. Hindmarch I *et al.* "Psychopharmacological effects of sertraline in normal healthy volunteers." *Eur J Clin Pharm*, 1988;35(2): 221-223.
97. Mattila MJ *et al.* "Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age." *J Clin Psych*, 1988;49(8)(suppl): 52-58.

98. Sertraline Abridged International Registration Dossier for Obsessive-Compulsive Disorder, Feb. 1994. Clinical Expert Report, Part IC, Vol. 1, Table 11, pp. 54-57, Appendix D pp. 2-7.
99. Sertraline Abridged International Registration Dossier for Depression.
100. Sertraline Abridged International Registration Dossier for Panic Disorder, Sept. 1996.
101. Worldwide Labeling Safety Report: Sertraline and Mydriasis, June 7, 1999.
102. Worldwide Labeling Safety Report: Sertraline and Priapism, June 7, 1999.
103. Worldwide Labeling Safety Report: Sertraline and Allergic Reaction, June 7, 1999.
104. Worldwide Labeling Safety Report: Sertraline and Asthenia, June 7, 1999.
105. Worldwide Labeling Safety Report: Sertraline and Fatigue, June 7, 1999.
106. Worldwide Labeling Safety Report: Sertraline and Fever, June 7, 1999.
107. Worldwide Labeling Safety Report: Sertraline and Hot Flushes, June 7, 1999.
108. Worldwide Labeling Safety Report: Sertraline and Chest Pain, June 7, 1999.
109. Worldwide Safety Report: Sertraline and Hypertension, Aug. 9, 1999.
110. Worldwide Labeling Safety Report: Sertraline and Palpitations, June 7, 1999.
111. Worldwide Labeling Safety Report: Sertraline and Periorbital Edema, June 7, 1999.
112. Worldwide Labeling Safety Report: Sertraline and Syncope, June 7, 1999.
113. Worldwide Labeling Safety Report: Sertraline and Tachycardia, June 7, 1999.
114. Worldwide Labeling Safety Report: Sertraline and Coma, June 7, 1999.
115. Safety Evaluation & Epidemiology Report: Sertraline and Convulsions, Jan. 16, 1995.
116. Worldwide Labeling Safety Report: Sertraline and Headache, June 7, 1999.
117. Worldwide Labeling Safety Report: Sertraline and Migraine, June 7, 1999.
118. Safety Evaluation & Epidemiology Report: Sertraline and Movement Disorders, Mar. 10, 1995.
119. Worldwide Labeling Safety Report: Sertraline and Hyperkinesia, June 7, 1999.
120. Worldwide Labeling Safety Report: Sertraline and Hypertonia, June 7, 1999.
121. Worldwide Labeling Safety Report: Sertraline and Teeth Grinding, June 7, 1999.
122. Safety Evaluation & Epidemiology Report: Sertraline and Paresthesia, March 22, 1999.
123. Safety Evaluation & Epidemiology Report: Sertraline and Hypoesthesia, Jan. 17, 1995.

124. Worldwide Labeling Safety Report: Sertraline and Serotonin Syndrome, June 7, 1999.
125. Mills KC. "Serotonin Syndrome." *Clin Pharmacol*, 1995;52(5): 1475-1482.
126. Safety Evaluation & Epidemiology Report: Sertraline and Galactorrhea, Jan. 17, 1995.
127. Safety Evaluations & Epidemiology Report: Sertraline and Hyperprolactinemia, Feb. 2, 1995.
128. Worldwide Labeling Safety Report: Sertraline and Hypothyroidism, June 7, 1999.
129. Post-marketing spontaneous adverse event reports.
130. Safety Evaluation & Epidemiology Report: Sertraline and Pancreatitis, May 22, 1995.
131. Worldwide Safety Report: Sertraline and Bleeding-related Adverse Events, Mar. 17, 1999.
132. Worldwide Labeling Safety Report: Sertraline and Leukopenia, June 7, 1999.
133. Worldwide Labeling Safety Report: Sertraline and Thrombocytopenia, June 7, 1999.
134. Safety Evaluation & Epidemiology Report: Sertraline and Liver Events, Feb. 28, 1995.
135. Safety Evaluation & Epidemiology Report: Sertraline and Hyponatremia/SIADH, May 15, 1995.
136. Worldwide Labeling Safety Report: Sertraline and Hypercholesterolemia, June 7, 1999.
137. Safety Evaluation & Epidemiology Report: Sertraline and Agitation, Mar. 8, 1995.
138. Safety Evaluation & Epidemiology Report: Sertraline and Aggressive Reaction, Apr. 5, 1995.
139. Safety Evaluation & Epidemiology Report: Sertraline and Anxiety, Mar. 24, 1995.
140. Safety Evaluation & Epidemiology Report: Sertraline and Depression, Mar. 13, 1995.
141. Safety Evaluation & Epidemiology Report: Sertraline and Hallucination, Mar. 6, 1995.
142. Safety Evaluation & Epidemiology Report: Sertraline and Psychosis, Feb. 24, 1995.
143. Safety Evaluation & Epidemiology Report: Sertraline and Menstrual Disorders, Mar. 3, 1995.
144. Worldwide Labeling Safety Report: Sertraline and Bronchospasm, June 7, 1999.
145. Worldwide Labeling Safety Report: Sertraline and Alopecia, June 7, 1999.
146. Worldwide Labeling Safety Report: Sertraline and Angioedema, June 7, 1999.
147. Safety Evaluation & Epidemiology Report: Sertraline and Rash, Mar. 10, 1995.
148. Worldwide Labeling Safety Report: Sertraline and Face Edema, June 7, 1999.
149. Worldwide Labeling Safety Report: Sertraline and Urinary Retention, June 7, 1999.

150. Worldwide Labeling Safety Report: Sertraline and Dependence/Withdrawal Syndrome, Feb. 18, 1998.
151. Spontaneous adverse event report, AEM #9716373.
152. Goldney RD *et al.* "Direct-cost survey of SSRI overdose." *Med J Austral*, 1995;162: 568-569.
153. Worldwide Safety Report: Sertraline overdose and associated adverse events, Apr. 2, 1999.
154. Koe BK, Weissman A, Welch WM *et al.* Sertraline, 1S, 4S-N-Methyl-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthylamine, a New Uptake Inhibitor with Selectivity for Serotonin. *J Pharmacol Exper Ther.* 1983; 226(3): 686-700.
155. Sanders-Bush E, Breeding M, Knoth K, Tsutsum, M. Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. *Psychopharmacol* 1980; 99:64-69.
156. Lucki I, Kreider MS, Simansky KJ. Reduction of feeding behavior by the serotonin uptake inhibitor sertraline. *Psychopharmacology.* 1988; 96: 289-295.
157. Kleven MS and Woolverton WL. "Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys." *Drug and Alc Dependence* 1993;31: 149-158.
158. Vanover KE *et al.* "Evaluation of the discriminative stimulus and reinforcing effects of sertraline in rhesus monkeys." *Pharmacol, Biochem and Behav*, 1992;41: 789-793.
159. Warrington SJ. "Clinical Implications of the Pharmacology of Sertraline." *Int Clin Psychopharmacol*, 1991;6(suppl. 2): 11-21.
160. Saletu B, Grunberger J, Linzmayer L. On central effects of serotonin re-uptake inhibitors: a quantitative EEG and psychometric studies with sertraline and zimelidine. *J Neural Transm.* 1986; 67: 241-266.
161. Pages LJ, Garg DC, Martinez JJ, *et al.* Safety and pharmacokinetics of sertraline in healthy young males. *J Clin Pharmacol.* 1988; 28: 908-959.
162. *Study 10: The Metabolism and excretion of sertraline in man.* Sertraline HCl IRD, Vol. 4, Sept. 1988, p. 281-307.
163. Sertraline Tablets IRD, Sept. 1988.
164. Sertraline Capsules IRD.
165. Sertraline PTSD IRD, July 2000.
166. Worldwide Labeling Safety Report: Anaphylactoid Reaction and Sertraline, Aug. 14, 2001.
167. Worldwide Labeling Safety Report: Malaise and Sertraline, Aug. 14, 2001.
168. Worldwide Labeling Safety Report: Weight Decrease and Sertraline, Aug. 14, 2001.
169. Worldwide Labeling Safety Report: Weight Increase and Sertraline, Aug. 14, 2001.

170. Worldwide Labeling Safety Report: Edema Peripheral and Sertraline, Aug. 14, 2001.
171. Worldwide Labeling Safety Report: Muscle Contractions Involuntary and Sertraline, Aug. 14, 2001.
172. Worldwide Labeling Safety Report: Gynecomastia and Sertraline, Aug. 14, 2001.
173. Worldwide Labeling Safety Report: Syndrome of Inappropriate ADH Secretion and Sertraline, Aug. 14, 2001.
174. Worldwide Labeling Safety Report: Appetite Increased and Sertraline, Aug. 14, 2001.
175. Worldwide Labeling Safety Report: Constipation and Sertraline, Aug. 14, 2001.
176. Worldwide Labeling Safety Report: Tinnitus and Sertraline, Aug. 14, 2001.
177. Worldwide Labeling Safety Report: Arthralgia and Sertraline, Aug. 14, 2001.
178. Worldwide Labeling Safety Report: Euphoria and Sertraline, Aug. 14, 2001.
179. Worldwide Labeling Safety Report: Libido Decreased–Female and Sertraline, Aug. 14, 2001.
180. Worldwide Labeling Safety Report: Libido Decreased–Male and Sertraline, Aug. 14, 2001.
181. Worldwide Labeling Safety Report: Paroniria and Sertraline, Aug. 14, 2001.
182. Worldwide Labeling Safety Report: Yawning and Sertraline, Aug. 14, 2001.
183. Worldwide Labeling Safety Report: Photosensitivity Skin Reaction and Sertraline, Aug. 14, 2001.
184. Worldwide Labeling Safety Report: Pruritus and Sertraline, Aug. 14, 2001.
185. Worldwide Labeling Safety Report: Stevens-Johnson Syndrome and Sertraline, Aug. 14, 2001.
186. Worldwide Labeling Safety Report: Epidermal Necrolysis and Sertraline, Aug. 14, 2001.
187. Worldwide Labeling Safety Report: Urticaria and Sertraline, Aug. 14, 2001.
188. Worldwide Labeling Safety Report: Urinary Incontinence and Sertraline, Aug. 14, 2001.
189. Worldwide Labeling Safety Report: Vision Abnormal and Sertraline, Aug. 14, 2001.
190. Sertraline and Fatal Cases of Drug Interaction with Monoamine Oxidase Inhibitors; Worldwide Safety Report, April 8, 1997.
191. Worldwide Labeling Safety Report: Sertraline and Stevens-Johnson Syndrome or Epidermal Necrolysis, June 7, 1999.
192. Kessler RC *et al.* “Comorbidity of DSM-III-R Major Depressive Disorder in the General Population: Results from the US National Comorbidity Survey.” *Br J Psych*, 1996; 168(suppl. 30): 17-30.

193. Peterson EL, Breslaw N and Kessler RC. Large same-year effects: Fact or artifact? *Br J Psych*, 1997;171: 487-8.
194. Schmidt AW, Peroutka SJ. Antidepressant interactions with 5-hydroxytryptamine₃ receptor binding sites. *Eur J Pharmacol*. 1989; 163: 397-398.
195. Doogan DP, Caillard V. Sertraline: A New Antidepressant. *J Clin Psychiatry* Aug 1988; 49:8 (Suppl): 46-51.
196. Sertraline HCl IRD. Vol 4 Sept 1988; Part III F. p.73-74.
197. Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. *J Clin Psychiatry* Dec 1990; 51:12 (suppl B), p. 13-17.
198. Wamsley KJ, McCabe RT, McConnell EJ, *et al*. Sertraline an antidepressant which inhibits serotonin uptake, specifically down regulates beta₁ receptors, (abstract 31.02.15) *Psychopharmacology* 1988; 96(Suppl): 270.
199. Koe BK, Koch SW, Lebel LA, *et al*. Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of beta-adrenoceptor system of rat brain. *Eur J Pharmacol*. 1987; 141:187-194.
200. Sertraline Depression IRD, Sept. 1988, Part III, Vol. 4, pp. 7-17, 80, 101.
201. Protocol 008: Phase I study comparing the bioequivalence of formulations of sertraline 100 mg as tablet and capsule with the 100 mg sertraline research capsule. Sertraline HCl IRD, Vol. 5.2, Sept. 1988, p. 155-186.
202. Protocol 001: Phase I single dose titration study to assess the safety and pharmacokinetics of sertraline. Sertraline HCl IRD, Vol. 5.2, Sept. 1988, p. 3-66.
203. *Protocol 006*: Phase I study comparing the bioequivalence of the research and commercial capsules of sertraline with a standard solution of sertraline at the 100 mg dose level. Sertraline HCl IRD, Vol. 5.2, Sept. 1988, p. 69-125.
204. *Protocol 208*: An open study of the pharmacokinetic profile of sertraline in elderly volunteers. Sertraline HCl IRD, Vol. 5.3, Sept. 1988, p. 440-485.
205. *Study 4*: Binding of sertraline in serum and blood. Sertraline HCl IRD, Vol. 4, Sept. 1988, Part IIG, p. 213-219.
206. Bolden-Watson C and Richelson E, Blockade by Newly Developed Antidepressants of Biogenic Amine Uptake into Rat Brain Synaptosomes. *Life Sciences*, 1993; 52: 1023-1029.
207. Sprouse J *et al*, Electrophysiological Evidence that Desmethylsertraline is Inactive at Blocking Central 5-HT Uptake *In Vivo*. Poster presented at XIX CINP, Washington, DC, USA, 24 June- 1 July, 1994.
208. *Protocol 007*: Phase I dose study to examine the metabolism and excretion of ¹⁴C sertraline. Sertraline HCl IRD, Vol. 5.3, Sept. 1988, p. 486-554.
209. *Study 2*: Pharmacokinetics of Sertraline in the Rat. Sertraline HCl IRD, Vol. 4, Sept. 1988, p. 193-199.

210. McEvoy GK, Litvak K, *et al.* Antidepressants. Sertraline Hydrochloride. American Hospital Formulary Service Drug Information. Bethesda, MD: Authority of the American Society of Health-System Pharmacists; 2000. 28:16.04, p. 2084-2085.
211. Worldwide Labeling Safety Report: Sertraline and Allergy, June 7, 1999.
212. Koran LM, Hackett, *et al.* Efficacy of Sertraline in the Long-Term Treatment of Obsessive-Compulsive Disorder, *Am J Psychiatry* Jan 2002; 159: 1: 88-95.
213. Rapaport MH, Wolkow R, *et al.* Sertraline treatment of panic disorder: Results of a long-term study, *Acta Psychiatr Scand* 2001; 104: 289-298.
214. Davidson J, Pearlstein T, *et al.* Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study, *Am J Psychiatry* 158: 12, Dec 2001: 1974-1981.
215. Social Phobia IRD, March 2002.
216. Walker JR, Van Ameringen M, Swinson R, *et al.* Prevention of Relapse in Generalized Social Phobia: Results of a 24-Week Study in Responders to 20 Weeks of Sertraline Treatment, *J Clin Psychopharmacol* Dec 2000; 20(6): 636-644.
217. Final Study Report: Sertraline Protocol A0501007. Phase I Open Study Designed to Determine the Potential Interaction of Sertraline with Cisapride or Pimozode in Healthy Male and Female Subjects. Pfizer Inc, July 20, 2001.
218. Pihlsgård M, Eliasson E. significant reduction of sertraline plasma levels by carbamazepine and phenytoin, *Eur J Clin Pharmacol* (2002) 57: 915-916.
219. Safety Analysis Report: Sertraline and Muscle Cramps dated 14Dec01.
220. Keller MB, Kocsis JH, *et al.* Maintenance Phase Efficacy of Sertraline for Chronic Depression. A Randomized Controlled Trial, *JAMA* Nov 18, 1998-Vol 280, No. 19: 1665-1672.
221. Chambers CD, Hernandez-Diaz S, *et al.* Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006;354:579-87.

Reference 222: CDS Revision Date 21 July 2008

222. 2.5 CLINICAL OVERVIEW, Sertraline Core Data Sheet Update (17 July 2008).

Reference 223: CDS Revision Date 13 January 2009

223. 2.5 CLINICAL OVERVIEW, Sertraline Core Data Sheet Update

Reference 224 and 225: CDS Revision Date 22 May 2009

224. 2.5 CLINICAL OVERVIEW, Review of Sertraline and Neuroleptic Malignant Syndrome

225. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. *Pharmacoeconomics and Drug Safety* 2008; 17:801-806.

Reference 226: CDS Revision Date July 2, 2009

226. 2.5 CLINICAL OVERVIEW, Sertraline and Persistent Pulmonary Hypertension of the Newborn (PPHN)

Reference 227: CDS Revision Date March 24, 2011

227. 2.5 CLINICAL OVERVIEW, Revisions to the Sertraline Product Labeling concerning Diabetes/Loss of Glycemic Control

Reference 228: CDS Revision Date May, 2011

228. 2.5 CLINICAL OVERVIEW, Association Between False-Positive Drug Screens for Benzodiazepines and the Use of Sertraline

Reference 229: CDS Revision Date September, 2011

229. 2.5 CLINICAL OVERVIEW, Sertraline and Angle-closure Glaucoma, Akathisia, Dystonia and Reversible Cerebral Vasoconstriction Syndrome (RCVS)

Reference 230: CDS Revision Date February, 2012

230. 2.5 Clinical Overview Sertraline CDS Revision_Bone Fracture_2012.
231. 2.5 Clinical Overview CP_051974_sertraline_2012 for CDS_MAOI interactions.
232. 2.5 Clinical Overview CP_051974_sertraline_2012 for CDS_overdose.
233. Sertraline_2012_Clinical Overview Non-renewal_CDS update for CDS_USPI_SPC_Health Canada Class Labeling
234. 2.5 Clinical Overview, Sertraline and Suicide/Suicidal Thoughts or Clinical Worsening
235. 2.5 Clinical Overview, Sertraline and QTc Prolongation
236. 2.5 Clinical Overview, Growth retardation
237. 2.5 Clinical Overview-Sertraline-Updates to Adverse Drug Reaction Frequency Categories of the Sertraline Company Core Data Sheet-February 2014

238. Non-Clinical Dossier, 2014-09 2.4 Sertraline Expert Report, 1988 dossier (pg 61, section 6.2.2) and 1994 dossier (pg 19, section 6.3).
239. 2.5 Clinical Overview Nonrenewal, Sertraline ODT Submission Emerging Markets, 2014
240. A0501098 Phase - 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Assessing Bioequivalence of Zoloft ODT 50 mg Under Fasting Condition With and Without Water to JZoloft[®] Tablet 50 mg Under Fasting Condition With Water in Healthy Japanese Subjects, Clinical Study Report. April, 2013.
241. Lau GT, Horowitz BZ, *et al.* Sertraline Overdose. Academic Emergency Medicine, Feb 1996; 3(2): 132-136.
242. Nelson LS, Erdman AR, *et al.* Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology 2007; 45: 315-332.
243. WR&D Memo: Sertraline Fertility Study Review. 05-February-2015
244. 2.5 Clinical Overview-Sertraline-CDS Update_Addition of ADR Trismus to Section 4.8_October 2016
245. 2.5 Clinical Overview-Sertraline-Addition of Adverse Drug Reaction Rhabdomyolysis to Section 4.8 Undesirable Effects of the Core Data Sheet, May 2017.
246. 2.5 Clinical Overview-Sertraline- To Support Addition of “Amphetamines” to the List of “Serotonergic Drugs” in Sections 4.4 and 4.5 of the Core Data Sheet, May 2017.
247. 2.5 Clinical Overview-Sertraline- To Support Updates to Section 5.1 Pharmacodynamic Properties of the Core Data Sheet Based on Clinical QT Study A0501104, May 2017.
248. Sertraline-Adverse Drug Reaction Frequency Justification Document, May 2017.
249. 2.5 Clinical Overview-Sertraline-To Support the Update of Sexual Dysfunction after Discontinuation to Section 4.4 Special Warnings and Precautions for Use of the Core Data Sheet, July 2019.
250. 2.5 Clinical Overview-Sertraline-To Support the Addition of Social Phobia Under Subsection Titration in Section 4.2 Posology and Method of Administration of the Core Data Sheet, November 2020.
251. 2.5 Clinical Overview-Sertraline-To Support Addition of Text Related to Postpartum Hemorrhage in Core Data Sheet and United States Prescribing Information, March 2021.
252. 2.5 Clinical Overview-Sertraline-Post-Authorization Safety Study (PASS) and Updates to CDS, March 2021.
253. 2.5 Clinical Overview-Sertraline-To Support the Increased Risk of Serotonin Syndrome Due to Opioids Interactions Updates to Section 4.4 Special Warnings and Precautions for Use of the Core Data Sheet, April 2021.